Document Detail


Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  3315574     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preliminary investigations using a single intracoronary dose of APSAC (up to 30U) revealed dissolution of intracoronary thrombi in 59 of 83 patients (71%) with acute myocardial infarction, as indicated by reperfusion of coronary arteries. Reocclusion of arteries occurred in 20.5% of patients. Based on these findings, a subsequent study was undertaken in 302 patients with evidence of recent acute myocardial infarction. Single intravenous bolus doses of APSAC (5 to 30U) produced reperfusion in 79% of patients, with reocclusion occurring in only 9% of patients receiving the higher doses. Adverse effects included an initial hypotension/bradycardia reaction, a later syndrome featuring pyrexia, nausea and vomiting, and bleeding complications, including 4 patients with cerebrovascular accidents. In these early studies APSAC appeared to be as effective as streptokinase, as reported in the literature, and to produce a lower incidence of reocclusion than tissue plasminogen activator.
Authors:
D Jackson
Related Documents :
3757184 - Risk stratification for 1 year survival based on characteristics identified in the earl...
3432204 - Prolonged diuretic administration and myocardial tolerance to ischaemia.
8625544 - Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intra...
10404864 - Effect of intravenous magnesium on heart rate and heart rate variability in patients wi...
23764484 - Myocardial infarct heterogeneity assessment by late gadolinium enhancement cardiovascul...
9138094 - Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  104-11     Citation Subset:  IM    
Affiliation:
Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Clinical Trials as Topic
Coronary Angiography
Coronary Circulation / drug effects
Dose-Response Relationship, Drug
Fibrinolytic Agents / adverse effects,  therapeutic use*
Heart Catheterization
Humans
Infusions, Intra-Arterial
Injections, Intravenous
Myocardial Infarction / drug therapy*
Plasminogen / adverse effects,  therapeutic use*
Streptokinase / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Highly differentiated adenocarcinoma in a villous adenoma of the common bile duct near the papilla
Next Document:  Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylat...